Home > Healthcare > Medical Devices > Diagnostic Devices > Multi Cancer Early Detection Market

Multi Cancer Early Detection Market Share

Report ID: GMI11171
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Multi Cancer Early Detection Market Share

The competitive landscape in the market is highly competitive and diverse, driven by technological innovation and product differentiation. Companies are heavily investing in research and development to enhance the sensitivity, accuracy, and specificity of their MCED tests. This includes the development of next-generation sequencing (NGS) platforms, AI-driven data analysis, and liquid biopsy technologies. Additionally, companies are partnering with academic institutions and research organizations to leverage innovative research and accelerate the development of new MCED tests.

Multi Cancer Early Detection Market Companies

Prominent players operating in the multi cancer early detection industry include:

AnPac Bio-Medical Science Co., Ltd.
Burning Rock Biotech Limited
EarlyDiagnostics
Elypta AB
EXACT SCIENCES CORPORATION
Freenome Holdings, Inc.
Genecast Biotechnology Co., Ltd.
Guangzhou AnchorDx Medical Co., Ltd.
GUARDANT HEALTH, INC.
Illumina, Inc. (GRAIL, Inc.)
Micronoma, Inc.
Oncocyte Corporation
Roche Holdings, Inc (FOUNDATION MEDICINE, INC.)
SeekIn Inc.
Singlera Genomics Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The multi cancer early detection industry size was valued at USD 1.3 billion in 2023 and is anticipated to witness a 14.8% CAGR between 2024 and 2032 driven by the rising prevalence of cancer, often attributed to lifestyle changes, including increased alcohol consumption and smoking.

The gene panel, LDT, & others segment in the multi cancer early detection industry attained USD 1.2 billion in 2023, due to technology's high throughput, accuracy, and declining costs.

North America multi cancer early detection market, generating revenues of USD 518.9 million in 2023, is expected to surge to USD 1.9 billion by 2032, due to substantial investments in next-generation sequencing (NGS) and liquid biopsy technologies.

AnPac Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, EarlyDiagnostics, Elypta AB, EXACT SCIENCES CORPORATION, and Freenome Holdings, Inc., among others.